



October 5, 2011

REGIONAL CLERK'S OFFICE
FILE No. - P41

Mr. Denis Kelly
Regional Clerk
Regional Municipality of York
17250 Yonge St.
Newmarket, ON L3Y 6Z1



RE: LYME DISEASE PETITION (2.0)

Dear Mr. Kelly:

This will confirm that at a meeting held on October 4, 2011, Council of the Town of Markham adopted the following resolution:

- "1) That the presentation by Ms. Jessica Bell Taliana entitled "Lyme Disease Petition" be received; and,
- 2) Whereas, the tick-borne illness known as Chronic Lyme Disease, which mimics many catastrophic illnesses, such as Multiple Sclerosis, Chohn's, Alzheimer's, arthritic diabetes, depression, Chronic Fatigue and Fibromyalgia is increasingly endemic in Canada, but the scientifically validated diagnostic tests and treatment choices are currently not available in Ontario, forcing patients to seek these in the United States of America and Europe; and,
- 3) Whereas, the *Canadian Medical Association* informed the public, governments, and the medical profession in May 30, 2000 edition of their professional journal that Lyme Disease is endemic throughout Canada, particularly in Southern Ontario; and,
- 4) Whereas, the Ontario Public Health system and the Ontario Health Insurance Plan currently do not fund those specific tests that accurately serve the process for establishing a clinical diagnosis, but only recognize testing procedures known in the medical literature to provide false negatives 45 to 95% of the time; and now,

.....2/

- 5) THEREFORE BE IT RESOLVED, that the Town of Markham request the Minister of Health to direct the Ontario Public Health system and OHIP to include all currently available and scientifically verified tests for Acute and Chronic Lyme diagnosis, to do everything necessary to create public awareness of Lyme Disease in Ontario, and to have internationally developed diagnostic and successful treatment protocols available to patients and physicians; and,
- 6) That the Council of the Town of Markham requests York Region's Community & Health Services Committee hear the presentation regarding Lyme Disease as soon as possible; and further,
- 7) That York Region prepare a response to the concerns regarding Lyme Disease and report back to York Region Council and York Region local municipalities on the results of their staff findings."

If you have any questions, please contact Alida Tari, Council/Committee Coordinator, at 905-477-7000 ext. 2211.

Yours sincerely,

A handwritten signature in black ink, appearing to read 'Kimberley Kitteringham', with a horizontal line extending to the right.

Kimberley Kitteringham
Town Clerk

KK:mbp



Bob
BAILEY
MPP • Sarnia-Lambton

PETITION

TO THE LEGISLATIVE ASSEMBLY OF ONTARIO

WHEREAS, the tick-borne illness known as Chronic Lyme Disease, which mimics many catastrophic illnesses, such as Multiple Sclerosis, Crohn's, Alzheimer's, arthritic diabetes, depression, Chronic Fatigue and Fibromyalgia is increasingly endemic in Canada, but the scientifically validated diagnostic tests and treatment choices are currently *not* available in Ontario, forcing patients to seek these in the USA and Europe;

WHEREAS, the *Canadian Medical Association* informed the public, governments, and the medical profession in May 30, 2000 edition of their professional journal that **Lyme Disease is endemic throughout Canada**, particularly in Southern Ontario;

WHEREAS, the Ontario Public Health system and the Ontario Health Insurance Plan currently do not fund those specific tests that accurately serve the process for establishing a clinical diagnosis, but only recognize testing procedures known in the medical literature to provide false negatives 45 to 95% of the time;

WE, THE UNDERSIGNED, petition the legislative assembly of Ontario to request the Minister of Health to direct the Ontario Public Health system and OHIP to include all currently available and scientifically verified tests for Acute and Chronic Lyme diagnosis, to do everything necessary to create public awareness of Lyme Disease in Ontario, and to have internationally developed diagnostic and successful treatment protocols available to patients and physicians.

Name (print clearly):	Address:
Signature:	Town/City:
E-mail Address:	Postal Code:

Name (print clearly):	Address:
Signature:	Town/City:
E-mail Address:	Postal Code:

Name (print clearly):	Address:
Signature:	Town/City:
E-mail Address:	Postal Code:

To date I have presented to six municipal councils and I am on the agenda of other municipalities in southern Ontario. I am also contacting all the municipalities in the province on this issue. Lambton County, Chatham Kent, Oxford County, Perth County, Middlesex and Huron County have endorsed the petition. Middlesex is reaching out to various advocacy groups that council members are a part of on the public's behalf on this issue. As well as endorsing the petition the County of Huron has sent a letter to Premier McGuinty asking him for action on "this very distressing disease that is affecting the livelihood of residents in Ontario". Chatham Kent is sending a letter to the Minister of Health to ask for action. The County of Perth is forwarding their support to their local MP and MPP to inform both the provincial and federal representatives for that area of their concern on this issue on behalf of the citizens that they represent.

My hope is that all municipal governments can lend their clout to this petition. It won't be long before everyone is affected in one way or another by this insidious disease. In the US this disease is now being called an epidemic by many health officials and its moving North. We need a strong response from our elected officials who are responsible for the public health of all the citizens of Ontario and Canada.

Thank you for taking the time to investigate this very urgent Public health issue.

Christine Heffer

Up dated list of MUNICIPALITIES endorsing the petition

Vaughan 300 000
Oro Medonte 18 000
Huron 59325
Perth 74344
Middlesex 69024
Lambton 128204
Oxford 102756
Chatham Kent 108177
Uxbridge 19169
Pickering 100273
Red Lake 4526
Smooth Rock Falls 1473
Quinte West 42697
Georgian Bluffs 10406
Huron Kinloss 6515
Mulmur 3318
Chatsworth 6392
Perry Sound 5818
North Kawarta 2342
Nation 10643
Loyalist 15062
Archipelago 576
Peterbrough 133080
Wainfleet 6601
magnetawan 1610
North Stormont 6769
stratford 32000
sequin 4276
gwillimburg 21069
stirling rawdon 2139
Gilles 28260
Cavan Monaghan 8828
Peterbrough 133080
Orangeville 26925
Highlands East 3089
Killarney 454
Nairn and Hyman 493
Limerick 3838
Drummond 6203
Temagami 934
French River 2659
Norfolk 62563

Ottawa
Confederation Building, Room 733
Ottawa, Ontario
K1A 0A6
Tel: (613) 996-4971
Fax: (613) 996-4973



House of Commons
Hon. Julian Fantino
Member of Parliament for Vaughan

Constituency
9401 Jane St. Building "A", Unit 15,
First Floor,
Vaughan, ON
L6A 4H7
Tel: (905) 303-5000
Fax: (905) 303-5002

Thursday, September 15th, 2011

Ms. Jessica Bell-Taliana
5451 Highway 7, Suite #108
Vaughan, Ontario
L4L 0B2

Re Chronic Lyme disease

Dear Ms. Bell-Taliana,

Thank you for contacting my office with regard to your efforts to raise awareness to the plight of Lyme disease. As the Canadian Medical Association has made Canadians aware, Lyme disease is endemic throughout Canada, particularly in Southern Ontario. This is an issue that affects families whose members have contracted this disease and have not properly been diagnosed due to ineffective testing methods.

The Ontario Public Health System and the Ontario Health Insurance Plan would benefit from re-examining the processes for establishing a clinical diagnosis. Your daughter's case serves as an example of the increasing need for the eligibility of Ontarians to receive the care they are not currently provided.

I wish you success in your ongoing efforts to tackle issues facing our community and the standard of health care they deserve.

Sincerely,

A handwritten signature in black ink, appearing to read 'J. Fantino'.

The Hon. Julian Fantino P.C., M.P.
Associate Minister of National Defence
Vaughan

Lyme disease is on the increase

Message from the Chief Medical Officer of Health

Ontario is seeing an increase in human cases of Lyme disease and an increase in numbers and range of black-legged ticks, especially in southern Ontario.

Reporting of all cases is critical.

Lyme disease is a preventable disease caused by a *Borrelia burgdorferi* bacterial infection and transmitted through the bite of an infected tick.

In Ontario, the black-legged tick (or deer tick) *Ixodes scapularis* is the sole vector of *B. burgdorferi*. People who spend time outdoors may encounter other tick species, but only the black-legged tick can transmit the Lyme disease bacteria. These ticks are small (3-5 mm) and people often do not realize they have a black-legged tick on them.

Risk Areas

The greatest risk of acquiring Lyme disease is found in areas where black-legged ticks carrying the bacteria are endemic (well-established).

The endemic areas in Ontario include:

- Long Point Provincial Park (northwest shore of Lake Erie near Port Rowan)
- Point Pelee National Park (near Leamington)
- Prince Edward Point National Wildlife Area (located at the southeastern tip of Prince Edward County)
- St. Lawrence Islands National Park (near Brockville)
- Rondeau Provincial Park (southeast of Chatham)
- Turkey Point Provincial Park (near Port Rowan)
- Wainfleet Bog Conservation Area (in Port Colborne)

The black-legged tick also feeds on birds and can be transported to almost anywhere in the province; therefore, Lyme disease can be acquired almost anywhere in the province.

When a person is showing signs and symptoms of Lyme disease, health care professionals should consider this diagnosis even if the person is not from, or has not visited, an endemic area.

Persons can come into contact with ticks from early spring to the end of fall. The ticks can also be active in the winter in areas with no snow and mild temperatures ($>4^{\circ}\text{C}$).

**Let's
Target
Lyme** 

www.ontario.ca/lyme

Highlights:

- Since 2005, there has been an increasing trend in the number of Lyme disease cases acquired in Ontario.

REPORT:

- Lyme disease is a reportable disease as per O. Reg. 559. Clinically diagnosed Lyme disease, even in the absence of laboratory confirmation, should be reported to your local public health unit.

TEST:

- While the probability is low, it is possible to acquire Lyme disease almost anywhere in Ontario. If you suspect Lyme disease, have the patient tested.

TREAT:

- Early treatment with appropriate antibiotics is important.

Information for Clinicians

Clinical Presentation

The incubation period for *B. burgdorferi* is usually one to four weeks after a bite from an infected tick. Early infection is characterized in 70 to 80 per cent of cases by erythema migrans, a skin lesion commonly known as a "bull's eye rash" (see picture, right).

Other early symptoms include fever, headache, muscle and joint pains, fatigue and stiff neck. Clinical diagnosis can sometimes be difficult as the symptoms can mimic many other diseases.

If left untreated, Lyme disease can progress to an early-disseminated disease with migraines, weakness, multiple skin rashes, painful or stiff joints, cardiac abnormalities and extreme fatigue. If the disease continues, arthritis, along with neurological symptoms such as headaches, dizziness, numbness and paralysis can occur.



(see over)

 Ontario

Lyme Disease is on the increase

Treatment

If treated early with appropriate antibiotics, patients can expect to make a full recovery¹. People should seek medical attention if symptoms develop within 30 days of suspected tick exposure. If the patient still has the tick, or a health care professional removes it, submit the tick to the local public health unit where it will be sent for identification and Lyme bacteria testing (black-legged ticks only species tested). If the initial infection is not treated, then infection can become difficult to treat and patients may experience joint, heart and neurological symptoms.

Testing

Laboratory testing is used to support the diagnosis of Lyme disease and should be used in conjunction with clinical signs and symptoms². It is up to the attending physician to make the diagnosis and determine treatment. Patients tested during early infection may not have developed antibodies (negative serology) to the bacteria, making detection difficult; therefore, testing patients again in four weeks is recommended. Health Canada-approved blood tests are performed at the Ontario Public Health Laboratory and follow the recommendations of the Canadian Public Health Laboratory Network.

Testing patients for Lyme disease can be requested by writing "Lyme Serology" on the requisition form and providing clinical background.

The Centers for Disease Control and Prevention in the United States and the Public Health Agency of Canada caution health care professionals and the public regarding the use of private laboratories offering Lyme disease testing in the USA. These "for-profit" laboratories may not follow the same testing protocols as most provincial, state and federal laboratories in Canada and the USA.

Removing a Tick

- Using fine-tipped tweezers, carefully grasp the tick as close to the skin as possible. Pull it straight out, gently but firmly.
- Do not squeeze the tick. Squeezing can accidentally introduce Lyme bacteria into the body.
- Do not put anything on the tick, or try to burn the tick off.
- After tick removal, place it in a screw-top bottle (pill vial or film canister) and submit it to your local health unit for identification and testing. Establishing the type of tick will help assess the risk of acquiring Lyme disease.
- It is important to remember where the person most likely acquired the tick. It will help public health workers to identify areas of higher risk.
- Thoroughly cleanse the bite site with rubbing alcohol and/or soap and water.

If the tick is removed soon after its attachment, it will help to prevent infection as not all black-legged ticks are infected. An infected black-legged tick has to be feeding for at least 24 hours before it can transmit the bacteria to the human host.

For Further Information:

1. Canadian Family Physician: Lyme Disease, a zoonotic disease of increasing importance to Canadians. <http://www.cfp.ca/cgi/reprint/54/10/1381.pdf>
2. The laboratory diagnosis of Lyme borreliosis: Guidelines from the Canadian Public Health Laboratory Network. <http://www.pulsus.com/journals/abstract.jsp?HCtype=Physician&CurrPg=abstract&jnlKy=3&atlKy=7231&tsuKy=711&isArt=t&fromfold=&>
3. Erythema Migrans Lesions of Lyme Disease Photos. http://www.cdc.gov/acidod/dvbid/lyme/Id_LymeDiseaseRashPhotos.htm
4. Ontario Lyme Disease Fact Sheet <http://www.health.gov.on.ca/en/public/publications/disease/lyme.aspx>
5. Health Canada, It's Your Health: Lyme Disease http://www.hc-sc.gc.ca/hl-vs/alt_formats/pacrb-dgapcr/pdf/iyh-vs/diseases-maladies/lyme-eng.pdf
6. Public Health Agency of Canada: Ticks and Lyme Disease. <http://www.phac-aspc.gc.ca/d-mi/tickinfo-eng.php>

**Let's
Target
Lyme** 
www.ontario.ca/lyme



Ontario

LYME DISEASE INFORMATION

- Lyme disease is transmitted by the bite of a tick infected with *Borrelia burgdorferi* and results in a systemic infection similar to syphilis
- Many pathogens can be transmitted by one bite
 - ANAPLASMOSIS, BABESIOSIS, EHRLICHIOSIS, RICKETTSIA ROCKY MOUNTAIN SPOTTED FEVER (RMSF), STARI, TULAREMIA, BARTONELLA AND MANY MORE
- Lyme disease is the fastest growing infectious disease in North America with an estimated 400 000 cases per year in the US
- Lyme disease has been shown in studies to be increasing across Ontario especially in Southern Ontario
- Everyone is at risk especially children (age 2-14 highest risk group)
- Lyme disease is can be found everywhere, at parks, in yards, in gardens as ticks are transmitted by birds
- Public awareness, testing and treatment for this disease is poor
- If not caught early Lyme disease becomes chronic and incurable requiring long term treatment much like AIDS does
- A person infected with Lyme disease often becomes total disabled
- The far reaching effects of this disease on our communities include loss productivity , loss tax revenue, increased medical costs and increased burden on social services
- The Lyme bacteria has been found in semen
 - RECOVERY OF LYME SPIROCHETES BY PCR IN SEMEN SAMPLES OF PREVIOUSLY DIAGNOSED LYME DISEASE PATIENTS
Dr. Gregory Bach, Do.O., P.C. 2415 North Broad Street, Colmar, PA 18915
- Lyme disease can be passed congenitally
 - <http://www.canlyme.com/congenital.html>
- Tick borne diseases transmitted by blood
 - Transfusion-transmitted tick-borne infections: a cornucopia of threats. Leiby DA, Gill JE. Department of Transmissible Diseases, American Red Cross Holland Laboratory, Rockville, MD 20855, USA. Transfus Med Rev. 2004 Oct;18(4):293-306

INFORMATION ON TESTING

- In Ontario we use a 2-tiered testing system for Lyme disease
- 1st tier is the ELISA test (Enzyme-linked immunosorbent assay)
- 2nd tier is the WESTERN BLOT
- A person must receive a positive on the ELISA to move on to the WESTERN BLOT
- ELISA has been shown in numerous scientific studies to be faulty (references to some studies and a complete study to follow)
- **IMPORTANT TO NOTE ABOUT THE TESTING IN THE ACUTE FORM OF LYME DISEASE**
 - It takes a person 4-6 weeks to develop antibodies to the bacteria (this is what the ELISA measures)
 - If the person receives antibiotics early in the infection the body often will not mount a strong antibody reaction due to the antibiotics killing the bacteria
 - Often the ELISA test will come back negative for said patients early in the infection yet doctors are relying on the test and tell patients that they do not have Lyme disease based on this test yet the person could very well be infected and is now not receiving treatment

REFERENCES ON LYME DISEASE

Scientific Studies on the faultiness of the ELISA test used for testing for Lyme in Ontario

1. Tilton RC, Sand MN, Manak M. The Western immunoblot for Lyme disease: determination of sensitivity, specificity, and interpretive criteria with use of commercially available performance panels. Clin Infect Dis 1997;25(Suppl 1):S31-4.
2. Schmitz JL, Powell CS, Folds JD. Comparison of seven commercial kits for detection of antibodies to *Borrelia burgdorferi*. Eur J Clin Microbiol Infect Dis 1993;12:419-24
3. Engstrom SM, Shoop E, Johnson RC. Immunoblot interpretation criteria for serodiagnosis of early Lyme disease. J Clin Microbiol 1995;33:419-27.
4. C. W. Ang & D. W. Notermans & M. Hommes & A. M. Simoons-Smit & T. Herremans Large differences between test strategies for the detection of anti-*Borrelia* antibodies are revealed by comparing eight ELISAs and five immunoblots Eur J Clin Microbiol Infect Dis DOI 10.1007/s10096-011-1157-6

Studies on the spread of Lyme disease throughout Canada and Ontario

1. Birds Disperse Ixodid (Acari: Ixodidae) and *Borrelia burgdorferi*-Infected Ticks in Canada Authors: Scott, John D.; Fernando, Keerthi; Banerjee, Satyendra N.; Durden, Lance A.; Byrne, Sean K.; Banerjee, Maya; Mann, Robert B.; Morshed, Muhammad G. Source: Journal of Medical Entomology, Volume 38, Number 4, July 2001 , pp. 493-500(8)
2. Presence of spirochete causing Lyme disease, *Borrelia burgdorferi*, in the blacklegged tick, *Ixodes scapularis*, in southern Ontario S N Banerjee, M Banerjee, K Fernando, J D Scott, R Mann, and M G Morshed CMAJ. 2000 May 30; 162(11): 1567-1569.
3. The rising challenge of Lyme borreliosis in Canada, Canada Communicable Disease Report 1 January 2008 -Volume 34 -Number 01 NH Ogden, DPhil, (1), LR Lindsay, PhD, (2), M Morshed, PhD, (3), PN Sockett, PhD, (4), H Artsob, PhD, (2)
4. *Ixodes scapularis* ticks collected by passive surveillance in Canada: analysis of geographic distribution and infection with Lyme borreliosis agent *Borrelia burgdorferi*. Ogden NH, Trudel L, Artsob H, Barker IK, Beauchamp G, Charron DF, Drebot MA, Galloway TD, O'Handley R, Thompson RA, Lindsay LR. J Med Entomol. 2006 May;43(3):600-9

ARTICLE

Large differences between test strategies for the detection of anti-*Borrelia* antibodies are revealed by comparing eight ELISAs and five immunoblots

C. W. Ang · D. W. Notermans · M. Hommes ·
A. M. Simoons-Smit · T. Herremans

Received: 21 July 2010 / Accepted: 1 January 2011

© The Author(s) 2011. This article is published with open access at Springerlink.com

Abstract We investigated the influence of assay choice on the results in a two-tier testing algorithm for the detection of anti-*Borrelia* antibodies. Eighty-nine serum samples from clinically well-defined patients were tested in eight different enzyme-linked immunosorbent assay (ELISA) systems based on whole-cell antigens, whole-cell antigens supplemented with VlsE and assays using exclusively recombinant proteins. A subset of samples was tested in five immunoblots: one whole-cell blot, one whole-cell blot supplemented with VlsE and three recombinant blots. The number of IgM- and/or IgG-positive ELISA results in the group of patients suspected of *Borrelia* infection ranged from 34 to 59%. The percentage of positives in cross-reactivity controls ranged from 0 to 38%. Comparison of immunoblots yielded large differences in inter-test agreement and showed, at best, a moderate agreement between tests. Remarkably, some immunoblots gave positive results in samples that had been tested negative by all eight ELISAs. The percentage of positive blots following a positive ELISA result depended heavily on the choice of ELISA-immunoblot combination. We conclude that the assays used to detect anti-*Borrelia* antibodies have widely divergent sensitivity and specificity. The choice of ELISA-immunoblot combination severely influences the number of positive results, making the exchange of test results between laboratories with different methodologies hazardous.

Introduction

Lyme disease is caused by *Borrelia* spp. In Europe, infection is mostly caused by *B. afzelii* and *B. garinii*, while in the United States, *B. burgdorferi sensu stricto* is the causative agent [1]. Lyme disease manifests in a myriad of clinical ways, including erythema migrans, arthritis, carditis and neuroborreliosis [1]. Extracutaneous Lyme disease requires laboratory confirmation by culture, polymerase chain reaction (PCR) or antibody determination [2, 3]. Culture is only available in a limited number of laboratories, and the value of PCR in the diagnosis of various forms of Lyme disease is of limited use [2, 3]. Therefore, serological assays are the main method used to diagnose extracutaneous forms of Lyme disease.

Current guidelines for the diagnosis of Lyme disease include a two-tier testing algorithm [2, 3]. First, an enzyme-linked immunosorbent assay (ELISA) is performed, followed by the confirmation of positive ELISA results with an immunoblot. This two-step procedure was initiated because first-generation ELISAs for the detection of anti-*Borrelia* antibodies lacked specificity. The inclusion of a second, more specific, serological method made it possible to exclude false-positive ELISA samples [2, 4].

Many diagnostic assays are currently commercially available, and manufacturers have developed them to increase their sensitivity and specificity. During the last decade, assays using a peptide from the sixth invariant region (C6) of the variable major protein-like sequence-expressed (VlsE) of *B. burgdorferi* have been shown to be promising [5, 6]. Laboratories can choose between ELISAs and immunoblots using sonicated whole-cell antigens, whole-cell antigens combined with recombinant antigens (VlsE C6 peptide) and exclusively recombinant antigens. Due to this array of serological tests, there are an almost

C. W. Ang (✉) · M. Hommes · A. M. Simoons-Smit
VUMC,
Amsterdam, The Netherlands
e-mail: w.ang@vumc.nl

D. W. Notermans · T. Herremans
Centre for Infectious Disease Control Netherlands, National
Institute for Public Health and the Environment (RIVM),
Bilthoven, The Netherlands

indefinite number of possible combinations between ELISA and immunoblot in a two-tier testing scheme. Comparing anti-*Borrelia* test results between laboratories and studies may be impossible if tests with widely diverging sensitivities and specificities are used [7].

The aim of the present study was to compare a wide range of ELISA assays and immunoblots, based on either whole-cell or recombinant antigens, for detecting anti-*Borrelia* antibodies. We also aimed to investigate the influence of assay choice on results in a two-tier testing algorithm (ELISA followed by immunoblot). Therefore, we tested serum samples in eight ELISA systems and five immunoblots, covering the entire spectrum of native and recombinant antigens.

Patients and methods

Patients

Serum samples were selected from 89 clinically well-defined individuals. Fifty-nine samples were from patients suspected of *Borrelia* infection (skin manifestations, $n=8$; neurological symptoms, $n=26$; arthritic symptoms, $n=11$; ocular symptoms, $n=4$; other, $n=10$). Fourteen samples were from healthy controls and 16 came from patients with a high possibility for cross-reacting antibodies (syphilis patients, $n=10$; *Mycoplasma pneumoniae*-infected patients based on symptoms consistent with *M. pneumoniae* infection and a positive result for anti-*M. pneumoniae* IgM and IgG with a Virion/Serion ELISA, $n=6$).

Methods

Serum samples were tested in eight different ELISA systems. Three assays were based on sonicated whole-cell antigens (Diachem/Moran anti-*Borrelia*, VIDAS and Virion/Serion ELISA Classic *Borrelia burgdorferi*), three assays with sonicate whole-cell antigens supplemented with VlsE for IgG anti-*Borrelia* antibodies (Dade Behring Enzygnost Lyme link VlsE, Euroimmun Anti-*Borrelia* plus VlsE ELISA and Genzyme Virotech *Borrelia afzelii*+VlsE ELISA) and two assays using recombinant proteins (Immunetics C6 Lyme ELISA Kit and Mikrogen recomWell *Borrelia*). A subset of samples from 31 patients suspected of *Borrelia* infection were also tested in five different immunoblots. This group consisted of the following patients: skin manifestations, $n=3$; neurological symptoms, $n=15$; arthritic symptoms, $n=6$; ocular symptoms, $n=2$; other, $n=5$. One whole-cell blot (home-made using *B. afzelii* strain A39 cell sonicate, RIVM), one whole-cell blot supplemented with VlsE (Viramed *Borrelia* "MiQ"+VlsE ViraBlot) and three recombinant blots (Euroimmun Euroline-RN-AT, Mikrogen recom

Line *Borrelia* and Genzyme Virotech *Borrelia* Europe Line). A total of 31 samples were tested in all immunoblots.

Manufacturer-suggested cut-off levels and interpretation criteria were used for the ELISAs and immunoblots. Statistical analysis was performed using SPSS version 16.0 (SPSS Inc., Chicago, IL, USA).

Results

As expected, there was considerable discordance between the eight ELISAs. We tested 89 samples from patients and controls on all eight ELISAs. Of the complete set of serum samples, 35/89 (39%) were negative in all assays, while 16/89 (18%) were positive in all assays. The remaining 38/89 (43%) samples were positive in one to seven ELISAs.

In the 59 patients that were suspected of *Borrelia* infection, we observed a wide range of positive results, with percentages of positive ELISAs varying between 34 and 61% (Table 1). We did not observe a relation between the fraction of positive results and the nature of antigen used for the ELISA. The specificity of the ELISAs also varied widely. Although we had only small numbers of positive tests in healthy controls, some ELISAs produced up to 38% of positive tests in the cross-reactivity group (syphilis and *M. pneumoniae*-infected patients).

We aggregated results from the IgM and IgG tests and assessed them using a kappa statistic to determine agreement between the ELISAs. The kappa values ranged from 0.41 (moderate agreement) to 0.79 (substantial to good agreement), emphasising the differences between the ELISAs (Table 2). The choice of antigen does not seem to influence the level of agreement. Even the lowest kappa values were observed between two 'whole-cell+VlsE' ELISAs (0.43).

We tested a subset of 31 serum samples from patients suspected of *Borrelia* infection in all five immunoblots. Samples were from patients with positive and negative ELISA results, allowing us to investigate the specificity of the immunoblots. In general, we observed a much lower agreement for the immunoblots than for the ELISAs. Kappa values ranged from 0 (poor agreement) to 0.84 (good agreement), indicating that, for many samples, the outcome of the immunoblot is highly dependent on the choice of manufacturer (Table 3). Inter-blot agreement was disappointingly low for IgM and much higher for IgG (Table 3). Interestingly, recombinant blots did not have a higher agreement than whole-cell blots, and there was limited agreement even between recombinant blots. The highest agreement was for the home-made whole-cell blot with the Mikrogen recombinant blot. Additional analysis on the individual band level revealed similarly poor agreement, even in immunoblots containing recombinant antigens.

Table 1 Performance of eight enzyme-linked immunosorbent assay (ELISAs) in the three patient groups

ELISA manufacturer	Antigen used for ELISA	Number of positive samples (%)			Total number of tested samples
		Patients suspected for <i>Borrelia</i> infection	Cross-reactivity controls	Healthy controls	
Diacheck/Moran	Whole-cell	20/59 (34%)	2/16 (13%)	1/14 (7%)	89
VIDAS	Whole-cell	31/59 (53%)	4/16 (25%)	1/14 (7%)	89
Virion/Serion	Whole-cell	24/59 (41%)	1/16 (6%)	0/14	89
Enzygnost	Whole-cell+VlsE	23/59 (39%)	0/16	0/14	89
Euroimmun	Whole-cell+VlsE	29/59 (49%)	3/16 (19%)	0/14	89
Virotech	Whole-cell+VlsE	35/59 (59%)	6/16 (38%)	0/14	89
Immunetics	Recombinant	22/59 (37%)	0/16	0/14	89
Mikrogen	Recombinant	24/59 (41%)	3/16 (19%)	0/14	89

When performing eight different ELISAs and five different blots, there are 40 possible ELISA–blot combinations. Thirty-one samples were tested in all 40 combinations. A score of 0 indicates a negative result in all ELISAs and all blots, while a score of 40 indicates a positive result in all ELISAs and all blots. A score between 0 and 40 indicates that not all possible combinations yielded a positive result (i.e. disagreement between various ELISA–blot combinations). Of this small sample cohort, 20/31 (65%) had either a score of 0 or 40, indicating perfect agreement, irrespective of the ELISA–blot combination used. Discordant interpretations were generated in the other 35% of samples.

The influence of assay choice is further illustrated by investigation of the relationship between each ELISA and the fraction of positive blots. Surprisingly, we found anti-*Borrelia* immunoblot reactivity in samples that were negative in all eight ELISAs. These are samples that normally would not have been tested in immunoblots. Again, this was not dependent on the nature of the antigen used for the immunoblot. For the Euroimmun immunoblot, 4/11 (36%) of the ELISA-negative samples were blot-positive. Some immunoblots also seem to lack sensitivity, since samples that were positive in six to all eight of the tested ELISAs remained negative in all immunoblots. Some

of these samples were from Lyme disease patients with a short duration of symptoms, confirming that ELISAs may have a higher sensitivity than immunoblots during the early phase of a *Borrelia* infection.

For some ELISA–blot combinations, only about half of the ELISA-positive samples could be confirmed by immunoblot (e.g. VIDAS ELISA–Virotech immunoblot, Table 4). The quality of the other ELISAs was so high that the majority of ELISA-positive samples were confirmed with immunoblots (e.g. Diacheck/Moran and Enzygnost ELISAs). When taking into account the lack of specificity of a number of the immunoblots, it is clear that the combination of a non-specific ELISA with a non-specific blot will lead to a high fraction of presumably false-positive test results.

The ELISA test value is the final factor influencing the fraction of positive confirmatory blots. Figure 1 depicts an example—values for the VIDAS and Immunetics C6 Lyme ELISA according to the immunoblot results of a whole-cell blot (home-made) and a recombinant blot (Mikrogen). For the VIDAS–home-made blot combination, it is difficult to indicate a cut-off value for the VIDAS ELISA with a good separation between blot-positives and blot-negatives. When using the Immunetics ELISA as a screening tool, it becomes clear that, irrespective of the blot method used,

Table 2 Agreement between ELISAs for detecting IgM and/or IgG anti-*Borrelia* antibodies (kappa values)

ELISA manufacturer	Antigen used for ELISA	Diacheck/Moran	VIDAS	Virion/Serion	Enzygnost	Euroimmun	Virotech	Immunetics
Diacheck/Moran	Whole-cell	-	-	-	-	-	-	-
VIDAS	Whole-cell	0.53	-	-	-	-	-	-
Virion/Serion	Whole-cell	0.67	0.69	-	-	-	-	-
Enzygnost	Whole-cell+VlsE	0.71	0.62	0.78	-	-	-	-
Euroimmun	Whole-cell+VlsE	0.71	0.45	0.56	0.56	-	-	-
Virotech	Whole-cell+VlsE	0.44	0.65	0.57	0.43	0.47	-	-
Immunetics	Recombinant	0.74	0.60	0.64	0.86	0.53	0.41	-
Mikrogen	Recombinant	0.79	0.53	0.63	0.68	0.67	0.44	0.65

Table 3 Agreement between immunoblots for detecting anti-*Borrelia* antibodies (kappa values)

Blot	Blot type	Home-made	Virablot	Euroimmun	Mikrogen	Virotech
IgM and IgG combined						
Home-made	Whole-cell	-	-	-	-	-
Virablot	Whole-cell+VlsE	0.55	-	-	-	-
Euroimmun	Recombinant	0.45	0.24	-	-	-
Mikrogen	Recombinant	0.74	0.42	0.29	-	-
Virotech	Recombinant	0.66	0.60	0.25	0.55	-
IgM						
Home-made	Whole-cell	-	-	-	-	-
Virablot	Whole-cell+VlsE	-1.57	-	-	-	-
Euroimmun	Recombinant	0.04	0.20	-	-	-
Mikrogen	Recombinant	0.42	0	0.26	-	-
Virotech	Recombinant	0.20	0.46	0.39	0.34	-
IgG						
Home-made	Whole-cell	-	-	-	-	-
Virablot	Whole-cell+VlsE	0.43	-	-	-	-
Euroimmun	Recombinant	0.43	0.24	-	-	-
Mikrogen	Recombinant	0.84	0.27	0.43	-	-
Virotech	Recombinant	0.71	0.63	0.30	0.56	-

samples with an index >4 are almost always blot-positive. These characteristics make it possible to define groups of ELISA-positive serum samples that do not need immunoblot confirmation.

Discussion

We studied the influence of the choice of detection method on the results of *Borrelia* serology. We found that *Borrelia* ELISAs and immunoblots for detecting anti-*Borrelia* antibodies have widely divergent sensitivity and specificity, and that immunoblots generally show limited agreement. Analysis of a large number of ELISA-immunoblot combinations revealed large differences between various test


strategies in a two-tier testing algorithm. Although we only studied a limited number of serum samples, our extensive approach allowed us to draw several conclusion based on our observations.

Theoretically, the use of recombinant antigens should lead to increased specificity and, possibly, increased sensitivity as well. This does not seem to be true for the currently available ELISAs and immunoblots for the detection of anti-*Borrelia* antibodies. We could not find a clear relationship between the fraction of positive tests, the specificity and the nature of the antigen used for the serological tests. ELISAs using sonicated whole-cell antigens can be sensitive and specific, while recombinant ELISAs may lack specificity. Therefore, manufacturer claims for the superior performance of assays using

Table 4 Fractions of blot-confirmed samples for 40 ELISA-immunoblot combinations

ELISA manufacturer	Antigen used for ELISA	Number of positive samples in ELISA/total number of samples	Blot				
			Whole-cell	Whole-cell+VlsE	Recombinant		
			Home-made	Virablot	Euroimmun	Mikrogen	Virotech
Diacheck/Moran	Whole-cell	12/31	11/12 (92%)	9/12 (75%)	11/12 (92%)	12/12 (100%)	9/12 (75%)
VIDAS	Whole-cell	19/31	11/19 (58%)	12/19 (63%)	13/19 (68%)	14/19 (74%)	10/19 (53%)
Virion/Serion	Whole-cell	15/31	11/15 (73%)	11/15 (73%)	13/15 (87%)	12/15 (80%)	9/15 (60%)
Enzygnost	Whole-cell+VlsE	12/31	11/12 (92%)	10/12 (83%)	10/12 (83%)	12/12 (100%)	10/12 (83%)
Euroimmun	Whole-cell+VlsE	14/31	11/14 (79%)	11/14 (79%)	12/14 (86%)	12/14 (86%)	9/14 (64%)
Virotech	Whole-cell+VlsE	17/31	11/17 (65%)	11/17 (65%)	13/17 (77%)	13/17 (77%)	9/17 (53%)
Immunetics	Recombinant	13/31	11/13 (85%)	10/13 (77%)	10/13 (77%)	13/13 (100%)	10/13 (77%)
Mikrogen	Recombinant	13/31	11/13 (85%)	9/13 (69%)	11/13 (85%)	12/13 (92%)	9/13 (69%)

Fig. 1 Enzyme-linked immunosorbent assay (ELISA) test values in relation to immunoblot results for the detection of anti-*Borrelia* antibodies



recombinant antigens for the detection of *Borrelia* antibodies must be interpreted with caution.

A two-tier testing algorithm for the detection of anti-*Borrelia* antibodies is recommended world-wide [2, 3, 6]. However, there are several reasons to reappraise the additional value of an immunoblot confirmatory test in a two-tier testing scheme.

First, the lack of specificity of some immunoblots is counter-intuitive. The immunoblot is used as a confirmatory test, although it can be argued that it is merely a supplemental test due to the inter-dependence of ELISAs and immunoblots [8]. Theoretically, the use of recombinant antigens should allow discrimination between a specific antibody reactivity, cross-reactive antibodies and true anti-*Borrelia* antibodies [4]. The presence of commercially available immunoblots with low specificity diminishes the value of the immunoblot as a confirmatory test [8]. Furthermore, the two-tier testing scheme was originally proposed to overcome the lack of specificity of *Borrelia* ELISAs. This study has shown that not all of the newer generation ELISAs using recombinant *Borrelia* antigens have improved specificity compared to older serological assays [9, 10].

Second, the low level of agreement between the different immunoblots is very disappointing, especially for IgM. This low level of agreement, even at the individual band level, makes it hard to compare immunoblot results from different manufacturers.

Third, a mismatch between immunoblot and ELISA may occur during the early phase of infection. There are numerous

examples—from this and other studies—in which patients with early Lyme disease were initially ELISA-positive and blot-negative [11]. In such cases, immunoblot seroconversion can only be documented in a follow-up sample, and, sometimes, even this option is blocked because antibiotic treatment may interfere with the development of the anti-*Borrelia* antibody response [12]. This is an example of better sensitivity in the ELISAs compared to the immunoblots. Without detailed knowledge of the clinical manifestations and illness duration, reporting these cases as 'negative' could lead to erroneous conclusions.

Finally, several groups can be discriminated based on the ELISA value [10]: a 'high positive' group exhibiting clinical symptoms consistent with a diagnosis of Lyme disease and which can be reported as 'positive' without confirmatory testing, a 'low positive' group in which confirmatory testing may be helpful and, lastly, a negative group that does not require any further investigation. We do not advocate abandoning the use of immunoblots to confirm anti-*Borrelia* antibodies, but we do think that only a selection of samples needs confirmatory blotting. Furthermore, knowledge about the lower sensitivity of immunoblots compared to some of the ELISAs is indispensable in interpreting results.

In conclusion, ELISAs and immunoblots for detecting anti-*Borrelia* antibodies have widely divergent sensitivity and specificity, and immunoblots for detecting anti-*Borrelia* antibodies have only limited agreement. Therefore, the choice of ELISA-immunoblot combination severely influ-

ences the number of positive results, making the exchange of test results between laboratories with different methodologies hazardous. The widespread availability of more specific and sensitive assays for the detection of anti-*Borrelia* antibodies will open the way for a reappraisal of the two-tier testing system.

Acknowledgements This work has been presented at the 20th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2010), Vienna, Austria, April 2010. The authors would like to acknowledge Stephen Johnston for editing the final manuscript.

Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

References

1. Stanek G, Fingerle V, Hunfeld KP, Jaulhac B, Kaiser R, Krause A, Kristoferitsch W, O'Connell S, OrNSTEIN K, Strle F, Gray J (2011) Lyme borreliosis: clinical case definitions for diagnosis and management in Europe. *Clin Microbiol Infect* 17(1):69–79
2. Wilske B, Zöller L, Brade V, Eifert H, Göbel UB, Stanek G, Pfister HW (2000) MIQ-12 Lyme-Borreliose (English Internet Version). In: Mauch H, Lütticken R, Gattermann S (eds) *Qualitätsstandards in der mikrobiologisch-infektiologischen Diagnostik*. Urban & Fischer Verlag, München Jena
3. Brouqui P, Bacellar F, Baranton G, Birtles RJ, Björnsdóttir A, Blanco JR, Caruso G, Cinco M, Fournier PE, Francavilla E, Jensenius M, Kazar J, Laferi H, Lakos A, Lotric Furlan S, Maurin M, Oteo JA, Parola P, Perez-Eid C, Peter O, Postic D, Raoult D, Tellez A, Tsakentis Y, Wilske B (2004) Guidelines for the diagnosis of tick-borne bacterial diseases in Europe. *Clin Microbiol Infect* 10(12):1108–1132
4. Wilske B, Fingerle V, Schulte-Spechtel U (2007) Microbiological and serological diagnosis of Lyme borreliosis. *FEMS Immunol Med Microbiol* 49(1):13–21
5. Liang FT, Steere AC, Marques AR, Johnson BJ, Miller JN, Philipp MT (1999) Sensitive and specific serodiagnosis of Lyme disease by enzyme-linked immunosorbent assay with a peptide based on an immunodominant conserved region of *Borrelia burgdorferi* vlsE. *J Clin Microbiol* 37(12):3990–3996
6. Steere AC, McHugh G, Damle N, Sikand VK (2008) Prospective study of serologic tests for Lyme disease. *Clin Infect Dis* 47(2):188–195
7. Bakken LL, Callister SM, Wand PJ, Schell RF (1997) Interlaboratory comparison of test results for detection of Lyme disease by 516 participants in the Wisconsin State Laboratory of Hygiene/College of American Pathologists Proficiency Testing Program. *J Clin Microbiol* 35(3):537–543
8. Wormser GP, Carbonaro C, Miller S, Nowakowski J, Nadelman RB, Sivak S, Aguero-Rosenfeld ME (2000) A limitation of 2-stage serological testing for Lyme disease: enzyme immunoassay and immunoblot assay are not independent tests. *Clin Infect Dis* 30(3):545–548
9. Jansson C, Carlsson SA, Granlund H, Wahlberg P, Nyman D (2005) Analysis of *Borrelia burgdorferi* IgG antibodies with a combination of IgG ELISA and VlsE C6 peptide ELISA. *Clin Microbiol Infect* 11(2):147–150
10. Smismans A, Goossens VJ, Nulens E, Bruggeman CA (2006) Comparison of five different immunoassays for the detection of *Borrelia burgdorferi* IgM and IgG antibodies. *Clin Microbiol Infect* 12(7):648–655
11. Wormser GP, Nowakowski J, Nadelman RB, Visintainer P, Levin A, Aguero-Rosenfeld ME (2008) Impact of clinical variables on *Borrelia burgdorferi*-specific antibody seropositivity in acute-phase sera from patients in North America with culture-confirmed early Lyme disease. *Clin Vaccine Immunol* 15(10):1519–1522
12. Aguero-Rosenfeld ME, Nowakowski J, Bittker S, Cooper D, Nadelman RB, Wormser GP (1996) Evolution of the serologic response to *Borrelia burgdorferi* in treated patients with culture-confirmed erythema migrans. *J Clin Microbiol* 34(1):1–9

EDUCATION FOR PHYSICIANS

- Very little is taught about Lyme disease and tick-borne diseases in medical school
- Often a person with Lyme disease is marginalized and ostracised by the medical community due to the lack of knowledge about this disease
- We need to focus on education especially for the GP's and the ER physicians who will see the Acute Lyme patient when this disease is curable
- We need doctors to treat right away and not be waiting for test results since the window to treat Acute Lyme disease is very narrow
- Presently the College of Physicians and Surgeons of Ontario cannot provide a Lyme Literate Physician anywhere in this province who is trained in how to treat late stage Lyme disease
- Due to the lack of available Lyme Specialists, residents of Ontario are forced to seek medical treatments in the US at their own expense often resulting in bankruptcy and those who can't seek treatment in the US become increasingly disabled and often face death.

http://www.radioowensound.com/news_item.php?NewsID=25803

http://www.radioowensound.com/news_item.php?NewsID=35942

<http://www.kelownadailycourier.ca/includes/datafiles/print.php?id=353070&title=Okanagan%20ticks%20a%20ticking%20time%20bomb%3CbR%3E>

<http://www.bcmj.org/articles/prevalence-tick-borne-pathogens-south-okanagan-british-columbia-active-surveillance-ticks-d>

<http://www.anapsid.org/lyme/matthewgoss/typeofticks.html>

http://host.madison.com/ct/news/local/health_med_fit/article_57d2f978-83c2-11df-bf04-001cc4c002e0.html

<http://www.50plus.com/health/protect-against-lyme-disease/34671/>
(note there are three pages to this article)

<http://www.cdc.gov/about/grand-rounds/archives/2011/May2011.htm>

http://articles.southbendtribune.com/2011-05-22/health/29572914_1_lyme-disease-untreated-lyme-lyme-cases

<http://www.healthyrockford.com/health/news/x1560863919/Rockford-patients-fight-for-chronic-Lyme-disease-treatment>

<http://www.telegraph.co.uk/health/8511954/Deadly-Lyme-disease-on-increase-as-more-of-us-spend-time-outdoors.html>

<http://health.nytimes.com/health/guides/disease/lyme-disease/news-and-features.html>

<http://www.nytimes.com/2008/07/15/health/15brod.html#>

<http://www.thespec.com/news/article/288224--waterloo-woman-launches-local-support-group-for-lyme-disease-sufferers>

<http://cornwallfreenews.com/2011/05/lyme-disease-rally-to-be-held-on-parliament-hill-may-6th-2011/>